Merck’s Roger Perlmutter steps up with a cash-heavy, $4.5 billion deal to ally with Seattle Genetics on an under-the-radar ADC and newly-approved Tukysa

While Gilead was crossing the last t’s and dotting the last i’s on their $21 billion deal to buy Immunomedics and their ADC for …

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Mer­ck’s Roger Perl­mut­ter steps up with a cash-heavy, $4.5 bil­lion deal to al­ly with Seat­tle Ge­net­ics on an un­der-the-radar ADC and new­ly-ap­proved Tukysa